Tìm kiếm thời gian thực
TopFind đang tìm các kết quả mới nhất cho tìm kiếm của bạn.
Chúng tôi đã xem 617 kết quả trực tiếp cho skyrizi risankizumab sdn bhd và thu hẹp còn 3 lựa chọn đáng so sánh trước nhất.
Các chủ đề nổi bật nhất trong danh sách này là Biologics và Immunology.
Nguồn: AbbVie Malaysia
Mô tả
The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies.
Phù hợp nhất cho
Malaysian medical services, Psoriasis treatment và Rheumatology care
Đánh giá
Nguồn: AbbVie Pharmaceuticals (Thailand) Ltd.
Mô tả
Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.
Phù hợp nhất cho
Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment và Long Term biologic therapy
Đánh giá
Nguồn: AbbVie Singapore
Mô tả
Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.
Phù hợp nhất cho
Regional medical reference, Singapore Based patients và Biologic therapy information
Đánh giá
| So sánh | Skyrizi (risankizumab) Sdn Bhd | Skyrizi (risankizumab) | Skyrizi (risankizumab) 150mg |
|---|---|---|---|
| Nguồn | AbbVie Malaysia | AbbVie Pharmaceuticals (Thailand) Ltd. | AbbVie Singapore |
| Mô tả | The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies. | Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading. | Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia. |
| Phù hợp nhất cho | Malaysian medical services, Psoriasis treatment và Rheumatology care | Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment và Long Term biologic therapy | Regional medical reference, Singapore Based patients và Biologic therapy information |
| Hành động | |||
| Đánh giá |
Nếu bạn muốn bắt đầu với lựa chọn cân bằng nhất, tôi đề xuất:
"Skyrizi (risankizumab) Sdn Bhd từ AbbVie Malaysia."
Tôi chọn mục này vì Ensures access to the authentic IL-23 inhibitor within Malaysia's pharmaceutical regulatory framework.